PL1913954T3 - Zastosowanie domeny eda fibronektyny - Google Patents

Zastosowanie domeny eda fibronektyny

Info

Publication number
PL1913954T3
PL1913954T3 PL06794018T PL06794018T PL1913954T3 PL 1913954 T3 PL1913954 T3 PL 1913954T3 PL 06794018 T PL06794018 T PL 06794018T PL 06794018 T PL06794018 T PL 06794018T PL 1913954 T3 PL1913954 T3 PL 1913954T3
Authority
PL
Poland
Prior art keywords
fibronectin
eda domain
eda
domain
Prior art date
Application number
PL06794018T
Other languages
English (en)
Inventor
Claude Leclerc
Sagastibelza Juan José Lasarte
Ayala Marta Gorraiz
Valtueña Jesús Prieto
Original Assignee
Proyecto De Biomedicina Cima S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S L filed Critical Proyecto De Biomedicina Cima S L
Publication of PL1913954T3 publication Critical patent/PL1913954T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/77Ovalbumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL06794018T 2005-06-13 2006-06-13 Zastosowanie domeny eda fibronektyny PL1913954T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200501412A ES2291071B1 (es) 2005-06-13 2005-06-13 Agentes y metodos basados en el uso del dominio eda de la fibronectina.
EP06794018A EP1913954B8 (en) 2005-06-13 2006-06-13 Use of the eda domain of fibronectin
PCT/ES2006/000343 WO2006134190A2 (es) 2005-06-13 2006-06-13 Agentes y métodos basados en el uso del dominio eda de la fibronectina

Publications (1)

Publication Number Publication Date
PL1913954T3 true PL1913954T3 (pl) 2013-01-31

Family

ID=37532656

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06794018T PL1913954T3 (pl) 2005-06-13 2006-06-13 Zastosowanie domeny eda fibronektyny

Country Status (14)

Country Link
US (2) US9155783B2 (pl)
EP (1) EP1913954B8 (pl)
JP (1) JP4970435B2 (pl)
CN (1) CN101287487B (pl)
AU (1) AU2006259041B2 (pl)
BR (1) BRPI0611782A2 (pl)
CA (1) CA2612151C (pl)
DK (1) DK1913954T3 (pl)
ES (2) ES2291071B1 (pl)
MX (1) MX2007015935A (pl)
PL (1) PL1913954T3 (pl)
PT (1) PT1913954E (pl)
RU (1) RU2430738C2 (pl)
WO (1) WO2006134190A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063865A1 (es) 2008-12-03 2010-06-10 Proyecto De Biomedicina Cima, S.L. Uso de modulinas solubles en fenol para el desarrollo de vacunas
WO2011029980A1 (es) * 2009-09-11 2011-03-17 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
EP2531207B1 (en) * 2010-02-05 2019-10-30 Cornell University Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
WO2011101332A1 (en) * 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
WO2012061750A2 (en) * 2010-11-04 2012-05-10 The Board Of Regents Of The University Of Oklahoma Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
WO2014136845A1 (ja) * 2013-03-06 2014-09-12 タカラバイオ株式会社 成熟樹状細胞集団の製造方法
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
FI3429618T3 (fi) 2016-03-16 2024-03-15 Amal Therapeutics Sa Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön
AU2017331949A1 (en) 2016-09-21 2019-01-31 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
WO2018162450A1 (en) * 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP4210734A1 (en) 2020-09-14 2023-07-19 Boehringer Ingelheim International GmbH Heterologous prime boost vaccine
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
WO2023174998A1 (en) 2022-03-16 2023-09-21 Boehringer Ingelheim International Gmbh Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108898A (en) * 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
WO2000076456A2 (en) * 1999-06-14 2000-12-21 The General Hospital Corporation Modulators of fibrosis
EP1188446B1 (en) * 2000-09-15 2009-08-05 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
IL162201A0 (en) * 2002-01-03 2005-11-20 Schering Ag New methods for diagnosis and treatment of tumours
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
FR2855758B1 (fr) * 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
US20060024725A1 (en) * 2004-07-30 2006-02-02 Robert Hussa Oncofetal fibronectin as a marker for pregnancy-related indications

Also Published As

Publication number Publication date
CN101287487B (zh) 2013-02-06
JP4970435B2 (ja) 2012-07-04
WO2006134190A8 (es) 2008-01-31
CA2612151C (en) 2015-01-13
US9155783B2 (en) 2015-10-13
ES2291071A1 (es) 2008-02-16
ES2291071B1 (es) 2009-03-16
EP1913954B1 (en) 2012-08-08
RU2430738C2 (ru) 2011-10-10
MX2007015935A (es) 2008-04-21
RU2008100242A (ru) 2009-07-20
AU2006259041A1 (en) 2006-12-21
WO2006134190A3 (es) 2007-02-22
EP1913954A4 (en) 2011-01-12
ES2392659T3 (es) 2012-12-12
EP1913954B8 (en) 2012-09-19
WO2006134190A2 (es) 2006-12-21
DK1913954T3 (da) 2012-11-26
EP1913954A2 (en) 2008-04-23
CA2612151A1 (en) 2006-12-21
US20160215039A1 (en) 2016-07-28
BRPI0611782A2 (pt) 2010-09-28
US20090220532A1 (en) 2009-09-03
JP2008543301A (ja) 2008-12-04
AU2006259041B2 (en) 2012-02-02
PT1913954E (pt) 2012-11-19
CN101287487A (zh) 2008-10-15

Similar Documents

Publication Publication Date Title
PL1913954T3 (pl) Zastosowanie domeny eda fibronektyny
GB0522715D0 (en) New use
EP1954329A4 (en) NEW VACUUM ITEM
GB0505954D0 (en) Novel use
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0510321D0 (en) Shower tray
GB0520176D0 (en) Use
EP1898940A4 (en) INTEGRIN INHIBITORS ALPHA2BETA1 / GPIA-IIA
GB0511190D0 (en) Use
GB0506001D0 (en) Novel use
GB0526552D0 (en) New use
GB0502250D0 (en) Use
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
GB0526031D0 (en) Use
GB0526032D0 (en) Use
EP1846443A4 (en) NEW USE
GB0525380D0 (en) SRCR-B domain containing proteins
GB0508924D0 (en) New use
GB0516862D0 (en) Potty
GB0513481D0 (en) Potty
GB0505961D0 (en) Shower tray
GB0606545D0 (en) Fibronectin type 111 domain containing protein
GB0515817D0 (en) New use
AU306394S (en) Shower
AU306395S (en) Shower